Should I Buy SNDX? SNDX 2026 Analysis

Should You Buy Syndax Pharmaceuticals Inc (SNDX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

20.590

1 Day change

0.19%

52 Week Range

22.730

Analysis Updated At

2026/01/26

Syndax Pharmaceuticals Inc (SNDX) is not a strong buy for a beginner, long-term investor at this moment. While the company shows significant revenue growth, its financial performance remains weak with declining net income and EPS. Insider selling and lack of recent positive news or catalysts further weaken the case for immediate investment. The technical indicators are neutral, and there is no strong signal from Intellectia Proprietary Trading Signals. Analysts remain optimistic with raised price targets, but the stock's current pre-market price does not present a compelling entry point for a long-term investment strategy.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 40.914, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 20.62, with support at 19.833 and resistance at 21.407.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have raised price targets recently, with Barclays and UBS showing optimism for future growth. Revenue growth of 266.97% YoY in Q3 2025 is a positive indicator.

Neutral/Negative Catalysts

Insiders are selling heavily, with a 195.05% increase in selling activity over the last month. Net income and EPS have declined significantly YoY. No recent news or event-driven catalysts. Lack of Congress trading data and no signals from Intellectia Proprietary Trading Signals.

Financial Performance

In Q3 2025, revenue increased by 266.97% YoY to $45.87M, but net income dropped by 27.83% YoY to -$60.72M. EPS fell by 28.57% YoY to -0.7, and gross margin decreased slightly to 95.42%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts remain optimistic with raised price targets: Barclays increased its target to $35 from $22, UBS raised it to $38 from $35, and JPMorgan adjusted its target to $33 from $40. All firms maintain positive ratings on the stock.

10 Analyst Rating

Wall Street analysts forecast SNDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNDX is 39.11 USD with a low forecast of 27 USD and a high forecast of 56 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 20.550

Low

Averages

39.11

High

Current: 20.550

Low

Averages

39.11

High

Barclays

NULL

Overweight

upgrade

$22 -> $35

AI Analysis

2025-11-24

Reason

Barclays

Price Target

$22 -> $35

AI Analysis

2025-11-24

upgrade

NULL

Overweight

Reason

Barclays raised the firm's price target on Syndax to $35 from $22 and keeps an Overweight rating on the shares. The firm updated the company's model after speaking with management.

JPMorgan

Anupam Rama

Overweight

downgrade

$40 -> $33

2025-11-12

Reason

JPMorgan

Anupam Rama

Price Target

$40 -> $33

2025-11-12

downgrade

Overweight

Reason

JPMorgan analyst Anupam Rama lowered the firm's price target on Syndax to $33 from $40 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SNDX

Unlock Now

SNDX Should I Buy

SNDX Should I Buy

Should You Buy Syndax Pharmaceuticals Inc (SNDX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch